Resultats globals: 3 registres trobats en 0.04 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
13 p, 1.2 MB Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy : A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research / Schoettler, M.L. (Children's Healthcare of Atlanta) ; Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cho, Byung-Sik (The Catholic University of Korea) ; Dandoy, Christopher E. (Cincinnati Children's Hospital Medical Center) ; Ho, Vincent Trien Vinh (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Jodele, Sonata (Cincinnati Children's Hospital Medical Center) ; Moissev, I. (Pavlov First Saint Petersburg State Medical University) ; Sańchez Ortega, Isabel (European Society for Bone Marrow Transplant) ; Srivastava, Alok (Christian Medical College Vellore) ; Atsuta, Yoshiko (Aichi Medical University) ; Carpenter, Paul A. (Seattle Children's Hospital) ; Koreth, John (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Kröger, Nicolaus M. (Ohio State. University) ; Ljungman, Per (Karolinska Institutet (Estocolm, Suècia)) ; Page, Kristin M. (Medical College of Wisconsin) ; Popat, Uday R. (The University of Texas MD Anderson Cancer Center) ; Shaw, Bronwen E. (Medical College of Wisconsin) ; Sureda Balari, Anna Maria (Institut Catala d'Oncologia-Hospital Duran i Reynals) ; Soiffer, Robert J. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Vasu, Sumithira V. (Ohio State. University)
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. [...]
2023 - 10.1016/j.jtct.2022.11.015
Transplantation and Cellular Therapy, Vol. 29 Núm. 3 (march 2023) , p. 151-163  
2.
8 p, 894.2 KB Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma / Kekre, N. (The Ottawa Hospital) ; Marquez-Malaver, Francisco J. (Instituto de Biomedicina de Sevilla) ; Cabrero, Monica (Instituto Biosanitario de Salamanca (IBSAL)) ; Piñana, J. (Hospital Clínic Universitari (València)) ; Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ; Soiffer, Robert J. (Dana Farber Cancer Institute) ; Caballero, Dolores (Instituto Biosanitario de Salamanca (IBSAL)) ; Terol, M.J. (Hospital Clínic Universitari (València)) ; Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Antin, Joseph H. (Harvard Medical School) ; Lopez-Corral, L. (Instituto Biosanitario de Salamanca (IBSAL)) ; Solano, Carlos (Hospital Clínic Universitari (València)) ; Armand, Philippe (Harvard Medical School) ; Pérez-Simon, Jose A. (Instituto de Biomedicina de Sevilla) ; Universitat Autònoma de Barcelona
There is at present little data to guide the choice of conditioning for patients with lymphoma undergoing reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). In this study, we compared the outcomes of patients undergoing RIC SCT who received fludarabine and melphalan (FluMel), the standard RIC regimen used by the Spanish Group of Transplantation, and fludarabine and busulfan (FluBu), the standard RIC regimen used by the Dana-Farber Cancer Institute/Brigham and Women's Hospital. [...]
2016 - 10.1016/j.bbmt.2016.07.006
Biology of blood and marrow transplantation, Vol. 22 Núm. 10 (january 2016) , p. 1808-1815  
3.
11 p, 572.5 KB Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group / Mohty, Mohamad (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ; Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ; Abecasis, Manuel (Instituto Portugues de Oncologia) ; Aerts, E. (University Hospital Zurich (Suïssa)) ; Alaskar, A. S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ; Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre) ; Arat, Mutlu (HSCT Unit. Sisli Florence Nightingale Hospital) ; Bader, Peter (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ; Baron, Frederic (CHU and University of Liege) ; Basak, G. (Medical University of Warsaw) ; Bazarbachi, A. (American University of Beirut. Department of Internal Medicine) ; Blaise, Didier (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ; Ciceri, Fabio (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ; Corbacioglu, Selim (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ; Dalle, J. H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ; Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ; Fukuda, T. (HSCT Division. National Cancer Center Hospital) ; Huynh, A. (Institut Universitaire du Cancer Toulouse-Oncopole) ; Kuball, J. (Department of Haematology. University Medical Centre) ; Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ; Lazarus, H. (Case Western Reserve University) ; Masszi, T. (St László Hospital (Hongria)) ; Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ; Nagler, Arnon (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ; NiChonghaile, M. (Trinity College Dublin) ; Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ; Pagliuca, A. (King's College Hospital NHS Foundation Trust) ; Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ; Petersen, F. B. (LDS Hospital) ; Richardson, Paul G.. (Division of Hematology. Mayo Clinic) ; Ruutu, T. (Helsinki University Hospital (Finlàndia)) ; Saber, Wael (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ; Savani, B. N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ; Soiffer, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Division of Hematologic Malignancies) ; Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ; Wallhult, E. (Sahlgrenska University Hospital (Suècia)) ; Yakoub-Agha, Ibrahim (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ; Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495  

Vegeu també: autors amb noms similars
2 Soiffer, Robert J.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.